0001193125-18-345427.txt : 20181210 0001193125-18-345427.hdr.sgml : 20181210 20181210060541 ACCESSION NUMBER: 0001193125-18-345427 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20181210 FILED AS OF DATE: 20181210 DATE AS OF CHANGE: 20181210 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ASLAN Pharmaceuticals Ltd CENTRAL INDEX KEY: 0001722926 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: E9 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38475 FILM NUMBER: 181224797 BUSINESS ADDRESS: STREET 1: 83 CLEMENCEAU AVENUE STREET 2: #12-03 UE SQUARE CITY: SINGAPORE STATE: U0 ZIP: 239920 BUSINESS PHONE: 65 6222 4235 MAIL ADDRESS: STREET 1: 83 CLEMENCEAU AVENUE STREET 2: #12-03 UE SQUARE CITY: SINGAPORE STATE: U0 ZIP: 239920 6-K 1 d644438d6k.htm FORM 6-K Form 6-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of December 2018

Commission File Number: 001-38475

 

 

ASLAN PHARMACEUTICALS LIMITED

(REG. NO. 289175)

(Exact name of Registrant as specified in its charter)

CAYMAN ISLANDS

(Jurisdiction of incorporation or organisation)

83 CLEMENCEAU AVENUE

#12-03 UE SQUARE

SINGAPORE 239920

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or

Form 40-F:    ☒  Form 20-F    ☐  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ☐

 

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

      ASLAN PHARMACEUTICALS LIMITED
Date:   10 December, 2018   By:  

/s/ Kiran Kumar Asarpota

    Name:  

Kiran Kumar Asarpota

    Title:  

VP Finance

ASLAN PHARMACEUTICALS LIMITED AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

(In U.S. Dollars)

(Unaudited)

 

 

     June 30, 2018     December 31, 2017  
     Amount     %     Amount     %  

ASSETS

         

CURRENT ASSETS

         

Cash and cash equivalents

    $ 44,952,396       65     $ 50,573,211       99  

Prepayments

      198,043       —         71,946       —    
  

 

 

    

 

 

    

 

 

    

 

 

  

Total current assets

      45,150,439       65       50,645,157       99  
  

 

 

    

 

 

    

 

 

    

 

 

  

NON-CURRENT ASSETS

         

Property, plant and equipment

      369,906       1       443,566       1  

Intangible assets

      23,083,850       34       84,052       —    

Refundable deposits

      191,739       —         160,947       —    
  

 

 

    

 

 

    

 

 

    

 

 

  

Total non-current assets

      23,645,495       35       688,565       1  
  

 

 

    

 

 

    

 

 

    

 

 

  

TOTAL

    $ 68,795,934       100     $ 51,333,722       100  
  

 

 

    

 

 

    

 

 

    

 

 

  

LIABILITIES AND EQUITY

         

CURRENT LIABILITIES

         

Trade payables

    $ 3,354,095       5     $ 3,898,291       8  

Other payables

      2,388,089       3       2,080,544       4  
  

 

 

    

 

 

    

 

 

    

 

 

  

Total current liabilities

      5,742,184       8       5,978,835       12  
  

 

 

    

 

 

    

 

 

    

 

 

  

NON-CURRENT LIABILITIES

         

Long-term borrowings

      9,715,329       14       9,679,451       19  

Other non-current liabilities

      486,000       1       162,000       —    
  

 

 

    

 

 

    

 

 

    

 

 

  

Total non-current liabilities

      10,201,329       15       9,841,451       19  
  

 

 

    

 

 

    

 

 

    

 

 

  

Total liabilities

      15,943,513       23       15,820,286       31  
  

 

 

    

 

 

    

 

 

    

 

 

  

EQUITY

         

Ordinary shares

      51,587,993       75       41,514,016       81  

Capital surplus

      111,334,877       162       84,282,681       164  

Accumulated deficits

      (110,070,449 )      (160 )      (90,283,261 )      (176 ) 
  

 

 

    

 

 

    

 

 

    

 

 

  

Total equity

      52,852,421       77       35,513,436       69  
  

 

 

    

 

 

    

 

 

    

 

 

  

TOTAL

    $ 68,795,934       100     $ 51,333,722       100  
  

 

 

    

 

 

    

 

 

    

 

 

  

 

1

ASLAN PHARMACEUTICALS LIMITED AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(In U.S. Dollars)

(Unaudited)

 

 

     For the Six Months Ended
June 30		  
     2018     2017  
     Amount     Amount  

OPERATING EXPENSES

     

General and administrative

    $ (5,871,931 )    $ (3,825,459 ) 

Research and development

      (13,945,341 )      (13,000,134 ) 
  

 

 

    

 

 

  

Total operating expenses

      (19,817,272 )      (16,825,593 ) 
  

 

 

    

 

 

  

LOSS FROM OPERATIONS

      (19,817,272 )      (16,825,593 ) 
  

 

 

    

 

 

  

NON-OPERATING INCOME AND EXPENSES

     

Other gains and losses

      264,287       (362,654 ) 

Finance costs

      (224,461 )      (204,756 ) 
  

 

 

    

 

 

  

Total non-operating income and expenses

      39,826       (567,410 ) 
  

 

 

    

 

 

  

LOSS BEFORE INCOME TAX

      (19,777,446 )      (17,393,003 ) 

INCOME TAX EXPENSE

      (9,742 )      —    
  

 

 

    

 

 

  

NET LOSS FOR THE PERIOD

      (19,787,188 )      (17,393,003 ) 
  

 

 

    

 

 

  

TOTAL COMPREHENSIVE LOSS FOR THE PERIOD

    $ (19,787,188 )    $ (17,393,003 ) 
  

 

 

    

 

 

  

LOSS PER SHARE

     

Basic

    $ (0.14 )    $ (0.15 ) 
  

 

 

    

 

 

  

 

2